Leveraging Parse’s cutting-edge GigaLab facility and Evercode chemistry, this partnership will generate massive, high-quality single cell RNA sequencing datasets at unprecedented speed, enabling AI-driven cancer research and drug discovery to better predict therapeutic resistance and guide future treatments.
Parse Biosciences, Wellcome Sanger Institute, and Helmholtz Munich Collaborate to Pioneer Cancer Plasticity Atlas for Therapy Response Prediction
Share: